Susan G. Arbuck, MD

Articles by Susan G. Arbuck, MD

Clinical Status and Optimal Use of Topotecan

ByChris H. Takimoto, MD, PhD,Susan G. Arbuck, MD

November 1st 1997

Topotecan (Hycamtin) is a promising new topoisomerase I-targeting anticancer agent that first entered clinical trials in 1989 under National Cancer Institute sponsorship in collaboration with SmithKline Beecham. In 1996, it

Latest Updated Articles

Clinical Status and Optimal Use of Topotecan
November 1st 1997

Susan G. Arbuck, MD

Articles by Susan G. Arbuck, MD

Clinical Status and Optimal Use of Topotecan

Latest Updated Articles

Trending on CancerNetwork

FDA Approves Relacorilant Combo in Platinum-Resistant Ovarian Cancers

Bevacizumab Biosimilar Shows Clinical Equivalence in Advanced NSCLC

Nadofaragene Firadenovec Label Update Approved in BCG-Unresponsive NMIBC

IMNN-001 Plus Neoadjuvant Chemo Improves OS in Advanced Ovarian Cancer

When To Consider a Re-Biopsy in the Metastatic CRPC Treatment Course